CorVel Corp
NASDAQ:CRVL

Watchlist Manager
CorVel Corp Logo
CorVel Corp
NASDAQ:CRVL
Watchlist
Price: 56.76 USD -1.11% Market Closed
Market Cap: $2.9B

CorVel Corp
Cash from Operating Activities

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

CorVel Corp
Cash from Operating Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Operating Activities CAGR 3Y CAGR 5Y CAGR 10Y
CorVel Corp
NASDAQ:CRVL
Cash from Operating Activities
$149.1m
CAGR 3-Years
20%
CAGR 5-Years
11%
CAGR 10-Years
12%
Quest Diagnostics Inc
NYSE:DGX
Cash from Operating Activities
$1.9B
CAGR 3-Years
3%
CAGR 5-Years
-1%
CAGR 10-Years
9%
CVS Health Corp
NYSE:CVS
Cash from Operating Activities
$10.6B
CAGR 3-Years
-13%
CAGR 5-Years
-8%
CAGR 10-Years
2%
Cigna Corp
NYSE:CI
Cash from Operating Activities
$9.6B
CAGR 3-Years
4%
CAGR 5-Years
-1%
CAGR 10-Years
13%
Laboratory Corporation of America Holdings
NYSE:LH
Cash from Operating Activities
$1.6B
CAGR 3-Years
-6%
CAGR 5-Years
-5%
CAGR 10-Years
5%
Guardant Health Inc
NASDAQ:GH
Cash from Operating Activities
-$184.8m
CAGR 3-Years
16%
CAGR 5-Years
-12%
CAGR 10-Years
N/A
No Stocks Found

CorVel Corp
Glance View

In the intricate world of healthcare management, CorVel Corporation stands as a pivotal player, harmonizing technology and service to streamline the complexities of risk management and cost containment. Founded in 1987, CorVel has relentlessly pursued the mission of enhancing workplace injury claims processes, reducing expenses while ensuring quality care for the injured. The company's foundation is built on its ability to provide innovative solutions through advanced technology platforms that automate and optimize the management of workers’ compensation, liability claims, and healthcare services. By integrating data analytics, artificial intelligence, and cutting-edge claims management software, CorVel enables employers, insurers, and third-party administrators to keep a tight rein on costs and improve outcomes through proactive decision-making and efficient service delivery. CorVel’s revenue model is intricately tied to its suite of diversified services. The company generates income through its extensive offerings in network solutions, bill review, case management, and pharmacy benefit management. Network solutions form the backbone, providing clients with access to a broad network of medical providers while negotiating favorable rates. Meanwhile, their robust bill review system ensures that every medical claim is scrutinized for accuracy and compliance, a process that helps clients avoid overpayments and recover funds. Case management services further augment their revenue, as skilled professionals facilitate rehabilitation efforts, coordinate care, and monitor recovery progress to encourage cost savings. Moreover, the pharmacy benefit management branch secures additional profit by optimizing prescription costs and improving medication adherence. Together, these services create a seamless ecosystem where CorVel captures significant value through efficiency gains and cost control, solidifying its position in the competitive healthcare management landscape.

CRVL Intrinsic Value
50.39 USD
Overvaluation 11%
Intrinsic Value
Price $56.76

See Also

What is CorVel Corp's Cash from Operating Activities?
Cash from Operating Activities
149.1m USD

Based on the financial report for Dec 31, 2025, CorVel Corp's Cash from Operating Activities amounts to 149.1m USD.

What is CorVel Corp's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 10Y
12%

Over the last year, the Cash from Operating Activities growth was 25%. The average annual Cash from Operating Activities growth rates for CorVel Corp have been 20% over the past three years , 11% over the past five years , and 12% over the past ten years .

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett